Manoukian Paul, Kuhnen Leo C, van Laarhoven Hanneke W M, Bijlsma Maarten F
Amsterdam UMC location University of Amsterdam, Center for Experimental and Molecular Medicine, Laboratory of Experimental Oncology and Radiobiology, Amsterdam, the Netherlands; Cancer Center Amsterdam, Cancer Biology, Amsterdam, the Netherlands.
Amsterdam UMC location University of Amsterdam, Center for Experimental and Molecular Medicine, Laboratory of Experimental Oncology and Radiobiology, Amsterdam, the Netherlands.
Crit Rev Oncol Hematol. 2025 Feb;206:104573. doi: 10.1016/j.critrevonc.2024.104573. Epub 2024 Nov 22.
Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis. Due to a lack of clear symptoms, patients often present with advanced disease, with limited clinical intervention options. The high mortality rate of PDAC is, however, also a result of several other factors that include a high degree of heterogeneity and treatment resistant cellular phenotypes. Molecular subtypes of PDAC have been identified that are thought to represent cellular phenotypes at the tissue level. The epigenetic landscape is an important factor that dictates these subtypes. Permissive epigenetic landscapes serve as drivers of molecular heterogeneity and cellular plasticity in developing crypts as well as metaplastic lesions. Drawing parallels with other cancers, we hypothesize that epigenetic permissiveness is a potential driver of cellular plasticity in PDAC. In this review will explore the epigenetic alterations that underlie PDAC cell states and relate them to cellular plasticity from other contexts. In doing so, we aim to highlight epigenomic drivers of PDAC heterogeneity and plasticity and, with that, offer some insight to guide pre-clinical research.
胰腺导管腺癌(PDAC)预后较差。由于缺乏明显症状,患者常以晚期疾病就诊,临床干预选择有限。然而,PDAC的高死亡率也是由其他几个因素导致的,这些因素包括高度的异质性和抗治疗的细胞表型。已确定的PDAC分子亚型被认为代表了组织水平上的细胞表型。表观遗传格局是决定这些亚型的一个重要因素。允许性表观遗传格局在发育中的隐窝以及化生病变中作为分子异质性和细胞可塑性的驱动因素。与其他癌症进行类比,我们假设表观遗传允许性是PDAC细胞可塑性的潜在驱动因素。在这篇综述中,我们将探讨构成PDAC细胞状态基础的表观遗传改变,并将它们与其他背景下的细胞可塑性联系起来。通过这样做,我们旨在突出PDAC异质性和可塑性的表观基因组驱动因素,从而为指导临床前研究提供一些见解。